Evidence based pathology: Are EGFR tests valid predictors of treatment response to erlotinib or gefitinib in patients with pulmonary adenocarcinoma?

被引：0
|
作者：
Dastane, A. M. [1 ]
Gupta, R. [1 ]
Mckenna, R. J. [1 ]
Marchevsky, A. [1 ]
机构：
[1] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA
来源：
LABORATORY INVESTIGATION | 2008年 / 88卷
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
1548
引用
收藏
页码：340A / 340A
页数：1
相关论文
共 50 条
  • [21] ERLOTINIB SALVAGE THERAPY IN PULMONARY ADENOCARCINOMA PATIENTS WHO HAD DISEASE PROGRESSED AFTER PREVIOUS EGFR-TKI TREATMENT AND PLATINUM-BASED CHEMOTHERAPIES
    Wu, Wen-Shuo
    Tsai, Chun-Ming
    Lee, Yu-Chin
    Perng, Reury-Perng
    Whang-Peng, Jacqueline
    Chen, Yuh-Min
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S904 - S904
  • [22] Erlotinib versus gefitinib for brain metastases in Asian patients with exon 19 EGFR-mutant lung adenocarcinoma: a retrospective, multicenter study
    Jiang, Ye
    Zhang, Jing
    Huang, Juanjuan
    Xu, Bo
    Li, Ning
    Cao, Lei
    Zhao, Mingdong
    BMC PULMONARY MEDICINE, 2018, 18
  • [23] Erlotinib versus gefitinib for brain metastases in Asian patients with exon 19 EGFR-mutant lung adenocarcinoma: a retrospective, multicenter study
    Ye Jiang
    Jing Zhang
    Juanjuan Huang
    Bo Xu
    Ning Li
    Lei Cao
    Mingdong Zhao
    BMC Pulmonary Medicine, 18
  • [24] Treatment response to osimertinib in a patient with leptomeningeal metastasis from lung adenocarcinoma following failure of gefitinib and erlotinib: A case report
    Li, Junjun
    Liu, Xiaomei
    Yuan, Caijun
    MOLECULAR AND CLINICAL ONCOLOGY, 2018, 9 (03) : 321 - 324
  • [25] Lung adenocarcinoma with good response to erlotinib after gefitinib treatment failure and acquired T790M mutation
    Wu, Shang-Gin
    Shih, Jin-Yuan
    Yu, Chong-Jen
    Yang, Pan-Chyr
    JOURNAL OF THORACIC ONCOLOGY, 2008, 3 (04) : 451 - 452
  • [26] Pulmonary Adenocarcinoma, Harboring Both an EGFR Mutation and ALK Rearrangement, Presenting a Stable Disease to Erlotinib and a Partial Response to Alectinib
    Yokoyama, Akira
    Tamura, Atsuhisa
    Miyakawa, Kazuko
    Kusaka, Kei
    Shimada, Masahiro
    Hirose, Takashi
    Matsui, Hirotoshi
    Kitani, Masashi
    Hebisawa, Akira
    Ohta, Ken
    INTERNAL MEDICINE, 2018, 57 (16) : 2377 - 2382
  • [27] SOMATIC EGFR MUTATIONS AND GENE AMPLIFICATION PREDICT RESPONSE TO GEFITINIB OR ERLOTINIB IN NSCLC: A META-ANALYSIS BASED ON A COMPREHENSIVE EGFR SOMATIC MUTATION DATABASE
    Dahabreh, I.
    Linardou, H.
    Kosmidis, P.
    Bafaloukos, D.
    Murray, S.
    ANNALS OF ONCOLOGY, 2008, 19 : 104 - 105
  • [28] A Favorable Treatment Response of Erlotinib in Lung Adenocarcinoma with Concomitant Activating EGFR Mutation and ROS1 Rearrangement
    Kim, Min Hwan
    Park, Yehyun
    Park, Hye Jung
    Ji, Ah-young
    Song, Changho
    Jin, Moo-Nyun
    Kim, Young Ju
    Kim, Sun Wook
    Lee, Jung-Hee
    Kim, In-Soo
    Kim, Hye Ryun
    Kim, Joohang
    Cho, Byoung Chul
    EWHA MEDICAL JOURNAL, 2014, 37 (01): : 46 - 51
  • [29] Gefitinib, an effective treatment option for patients with pulmonary enteric adenocarcinoma harboring compound EGFR L858R and A871G mutation
    Cui, Yujie
    Liang, Jinlong
    Kang, Xiyun
    Liu, Miaomiao
    Zhang, Qi
    Zhang, Hongzhen
    INVESTIGATIONAL NEW DRUGS, 2023, 41 (06) : 787 - 790
  • [30] Gefitinib, an effective treatment option for patients with pulmonary enteric adenocarcinoma harboring compound EGFR L858R and A871G mutation
    Yujie Cui
    Jinlong Liang
    Xiyun Kang
    Miaomiao Liu
    Qi Zhang
    Hongzhen Zhang
    Investigational New Drugs, 2023, 41 : 787 - 790
12345